Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling
Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 13778-13787
DOI: 10.1021/acs.jmedchem.4c00583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.08.2024. Verfasst von Feng-Yang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medici…. Hauptthemen laut MEDLINE: Rhodium, Wnt Signaling Pathway, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
Metal-based chemoimmunotherapy has recently garnered significant attention for its capacity to stimulate tumor-specific immunity beyond direct cytotoxic effects. Such effects are usually caused by ICD via the activation of DAMP signals. However, metal complexes that can elicit antitumor immune responses other than ICD have not yet been described. Herein, we report that a rhodium complex (Rh-1) triggers potent antitumor immune responses by downregulating Wnt/β-catenin signaling with subsequent activation of T lymphocyte infiltration to the tumor site. The results of mechanistic experiments suggest that ROS accumulation following Rh-1 treatment is a critical trigger of a decrease in β-catenin and enhanced secretion of CCL4, a key mediator of T cell infiltration. Through these properties, Rh-1 exerts a synergistic effect in combination with PD-1 inhibitors against tumor growth in vivo. Taken together, our work describes a promising metal-based antitumor agent with a noncanonical mode of action to sensitize tumor tissues to ICB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovati…
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510006, China.
ORCID-Profile: Taotao Zou, Ke-Bin Huang
Förderung
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China
Zitieren
APA
Wang, F. Y., Yang, L. M., Xiong, X. L., Yang, J., Yang, Y., Tang, J. Q., Gao, L., Lu, Y., Wang, Y., Zou, T., Liang, H., & Huang, K. B. (2024). Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling. Journal of Medicinal Chemistry, 67(16), 13778-13787. https://doi.org/10.1021/acs.jmedchem.4c00583
Vancouver
Wang FY, Yang LM, Xiong XL, Yang J, Yang Y, Tang JQ, et al. Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling. Journal of Medicinal Chemistry. 2024;67(16):13778-13787. doi:10.1021/acs.jmedchem.4c00583
BibTeX
@article{Wang2024,
author = {Wang, Feng-Yang and Yang, Liang-Mei and Xiong, Xiao-Lin and Yang, Jing and Yang, Yan and Tang, Jiu-Qin and Gao, Lei and Lu, Yuan and Wang, Yuan and Zou, Taotao and Liang, Hong and Huang, Ke-Bin},
title = {Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {16},
pages = {13778--13787},
doi = {10.1021/acs.jmedchem.4c00583}
}
EUVIMED